Glycoengineering Market Size, Share, and Industry Analysis, By Offering (Glycoengineering Platforms, Consumables, Services), By Workflow Stage (Glycan Design & Site Engineering, Cell Line Development & Host Engineering, Glycan Profiling & Characterization, Process Development & QC Testing), By Technology (Enzymatic Glycan Remodeling, Cell Line Glycoengineering, Genome Editing-Based Glycoengineering), By Application (Monoclonal Antibodies, Biosimilars, Vaccines, Cell & Gene Therapy), By End User (Pharmaceutical & Biotechnology Companies, CROs & CDMOs), and Regional Forecast till 2034

The global glycoengineering market was valued at USD 0.85 billion in 2025. The market is projected to grow from USD 0.98 billion in 2026 to USD 3.20 billion by 2034, exhibiting a CAGR of 15.9% during the forecast period.

Glycoengineering is a method of changing the properties of recombinant proteins by changing their glycosylation. This is done using in vivo (cellular) genetic technologies and/or in vitro enzymatic methods. The global market is emerging as an important growth area within biologics development as glycosylation plays a critical role in the safety, efficacy, stability, and clinical performance of therapeutic proteins. As pharmaceutical and biotechnology companies continue to develop monoclonal antibodies, biosimilars, vaccines, recombinant proteins, and cell and gene therapy products, the need to control and analyze glycan structures is increasing. Glycoengineering helps companies design biologics with improved therapeutic activity, better product consistency, reduced immunogenicity, and stronger manufacturing control. This is encouraging the wider adoption of these platforms and key partnerships among operating entities.

• For instance, in March 2026, Kyron. Bio partnered with Servier to advance precision glycosylation in antibody therapeutics. Under the agreement, the company would use its proprietary glycoengineering technology to glycoengineer an antibody selected by Servier, while Servier would fund the related research activities.

Furthermore, new offering launches, pipeline expansion, and partnerships by key operating companies strengthen their market position and support global market growth.

Glycoengineering Market Driver

Rising Demand for Glycoengineered Biologics to Improve Therapeutic Efficacy

The global market is growing given that pharmaceutical and biotechnology companies are increasingly focusing on biologics with better therapeutic performance. Glycosylation can influence how a biologic behaves in the body, including its immune activity, stability, safety, and consistency. As a result, companies are adopting glycoengineering platforms, cell line technologies, enzymatic remodeling tools, and glycan analysis workflows to design biologics with improved efficacy and more controlled product quality. This is especially important in monoclonal antibodies and next-generation biologics, where controlled glycan structures can help improve antibody function, reduce variability, and support stronger clinical outcomes. Key companies are actively participating in strategic partnerships to cater to the needs of the market.

• For instance, in December 2025, NeuImmune Inc collaborated with Ginkgo Bioworks Holdings, Inc. to develop innovations that strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (mAbs) to treat infection by filoviruses such as Ebola (EBOV) and Sudan Viruses (SUDV). Through the collaboration, the company aimed to leverage its proprietary geCHO BioDesign platform, capable of generating uniformly produced human-like glycoforms of therapeutic proteins and vaccine antigens.

Download Free sample to learn more about this report.

In January 2026, Springer Nature Link published an article titled ‘Glycan Profiles of FDA-Approved Therapeutic Antibodies: Insights from Regulatory Submissions.’  The article highlighted that glycosylation control is a commercially important requirement in approved antibody products, particularly in oncology and immune-mediated disorders. Cancer had 48 products with glycan assays for drug substance release and 36 products where Fc effector function was part of the mechanism of action. This shows that oncology antibodies have a stronger need for glycoengineering.

Glycoengineering Market Restraint

Technical Complexity in Controlling Glycan Structures across Biologic Manufacturing

The global market may face restraints given that controlling glycan structures during biologic manufacturing is technically complex and difficult to standardize. Glycosylation can change due to the cell line used, culture media, feeding strategy, process conditions, scale-up method, and manufacturing site. As a result, companies often need advanced analytical tools, skilled scientists, repeated process optimization, and strong comparability testing to maintain the desired glycan profile. This increases development cost, extends timelines, and can slow adoption among small and mid-sized biotech companies that do not have strong internal bioprocessing and glycan-analysis capabilities.

• For instance, in July 2025, Ultragenyx Pharmaceutical announced that the U.S. FDA issued a Complete Response Letter for its UX111 AAV gene therapy BLA, citing specific chemistry, manufacturing, and controls observations. Although not a glycoengineering-specific case, it showcases how biologic and advanced therapy approvals can be delayed when manufacturing and CMC documentation do not fully satisfy regulatory expectations.

Glycoengineering Market Opportunity

Emerging Role of Glycoengineering in Cell and Gene Therapy Development

The global market is expected to gain strong growth opportunities from the expanding cell and gene therapy sector. These therapies require a deeper understanding of cell-surface glycans, protein glycosylation, and glycan-protein interactions. Glycans can influence cell behavior, immune recognition, targeting, persistence, and therapeutic performance. As a result, companies developing advanced therapies are likely to use more glycan detection kits, lectin-based screening tools, glycan analysis workflows, and glycoengineering services to characterize cells better and improve product design. This creates a new opportunity for glycoengineering companies beyond traditional monoclonal antibodies and biosimilars.

• For instance, in July 2025, Vector Laboratories and Navinci launched the Glysite Explorer in situ PLA Glycan Detection Kit. The kit is designed to study protein glycosylation with spatial context in FFPE tissues, FFPE cell pellets, and fixed cells. These developments highlight how commercial glycan detection tools are moving closer to cell-based and tissue-based research workflows, supporting advanced therapy development, biomarker research, and functional proteomics.

Segmentation

Key Insights

The report covers the following key insights:

• Overview of Technological Advancements in Glycoengineering Platforms
• Regulatory Scenario, By Key Countries/Regions
• New Product Launches and Indication Expansions, By Key Players
• Key Industry Developments (Mergers, Collaborations, and Acquisitions)

Analysis by Offering

Based on offering, the global market is segmented into instruments, consumables, glycoengineering platforms, software & informatics, and services.

The consumables segment is expected to dominate the market. They are used repeatedly across glycan analysis, glycan remodeling, cell-line development, and quality testing workflows, which is a major factor propelling segment growth. Unlike instruments, consumables such as glycan labeling kits, enzymes, lectins, glycan standards, columns, buffers, and sample preparation kits are needed for every experiment, batch analysis, and validation run. As biologics companies increase glycan profiling for monoclonal antibodies, biosimilars, vaccines, and advanced therapies, the demand for recurring consumables rises directly. This creates a stable revenue base for suppliers and makes consumables the most commercially dominant offering segment.

• For instance, in June 2025, Ludger launched its Procainamide Release and Labeling Bundle Kit, which includes reagents and glycan standards required for N-glycan analysis of therapeutic samples. The kit includes PNGase F enzyme for in-solution N-glycan release, procainamide labeling reagents, and clean-up cartridges, showing how companies are commercializing ready-to-use consumable bundles for biologics glycan analysis.

Analysis by Workflow Stage

Based on workflow stage, the market is segmented into glycan design & site engineering, cell line development & host engineering, glycan remodeling/glycoform optimization, glycan profiling & characterization, process development & QC testing, and commercial manufacturing support.

The glycan profiling and characterization segment held the largest share of the glycoengineering market. Every glycoengineered biologic must be analyzed before it can move forward in development, comparability testing, process validation, or commercial manufacturing. Glycosylation can affect product activity, safety, stability, and batch consistency, so companies need glycan characterization at multiple points in the biologics lifecycle. This creates strong demand for LC-MS, UPLC, glycan kits, standards, software, and analytical services. Since profiling is required not only for engineered products but also for biosimilars and routine biologics QC, this segment has broader adoption than early-stage glycan design or site engineering.

• For instance, in 2025, Ludger launched its Procainamide Release and Labeling Bundle Kit for N-glycan analysis of therapeutic samples. The bundle includes the complete set of reagents and glycan standards required for N-glycan analysis, including PNGase F enzyme, procainamide labeling reagents, clean-up cartridges, and system suitability standards. This supports the segmental growth.

Analysis by Technology

Based on technology, the market is segmented into enzymatic glycan remodeling, cell line glycoengineering, genome editing-based glycoengineering, chemoenzymatic synthesis, and others.

The cell line glycoengineering segment is expected to dominate the market. Glycosylation is mainly controlled during biologic production. Companies use engineered CHO, HEK, human, insect, or other host-cell systems to produce antibodies and therapeutic proteins with desired glycan profiles. This technology is crucial as it can improve product consistency, support scalable manufacturing, and help developers control critical quality attributes from the beginning of the production process. As the biologics and biosimilar pipeline expands, the demand for reliable cell-line systems and host-engineering technologies increases, making this segment stronger than more specialized technologies such as chemoenzymatic synthesis.

• For instance, in April 2026, Thermo Fisher Scientific launched the Gibco CHOvantage GS Cell Line Development Kit, a next-generation integrated cell-line development platform designed to help biologics developers accelerate time to clinic while maintaining regulatory confidence and commercial scalability. The platform helps generate high-performing CHO cell lines, supports stable pools in as little as four weeks, and simplifies development-to-manufacturing transfer.

Analysis by Application

Based on application, the market is segmented into monoclonal antibodies, biosimilars, vaccines, cell & gene therapy, and others.

The monoclonal antibodies segment is anticipated to capture the largest market share. They represent one of the largest and most commercially advanced biologics categories where glycosylation directly affects therapeutic performance. Glycan structures on antibodies can influence antibody-dependent cellular cytotoxicity, immune activity, stability, serum half-life, and batch-to-batch consistency. Therefore, antibody developers use glycoengineering platforms, afucosylation technologies, glycan analysis tools, and QC workflows to improve efficacy and maintain product quality.

• For instance, in April 2025, ProBioGen announced that Ziihera, a therapeutic antibody developed using its proprietary GlymaxX technology, became commercially available. They stated that GlymaxX technology optimizes antibody activity by reducing fucose formation in antibody-producing cells, which can enhance ADCC activity.

Analysis by End User

Based on end user, the market is segmented into pharmaceutical & biotechnology companies, CDMOs/CROs, academic & research institutes, and others.

The pharmaceutical and biotechnology companies segment is expected to dominate the market. Those are the main developers of glycoengineered biologics, biosimilars, vaccines, and next-generation therapies. These companies use glycoengineering across discovery, cell-line development, process development, glycan characterization, comparability testing, and commercial manufacturing support. They also have stronger budgets, larger biologics pipelines, and greater regulatory responsibility compared to academic institutes and smaller service users. As a result, their spending on instruments, consumables, platforms, software, and outsourced services is higher, making them the leading customer group in the market.

• For instance, in September 2020, GlycoT Therapeutics LLC, in collaboration with the University of Maryland, Baltimore (UMB) and University of Maryland, College Park (UMCP), executed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo Company, Limited. The agreement granted Daiichi Sankyo worldwide and non-exclusive rights to IP that GlycoT currently licenses from UMB and UMCP.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, on the basis of region, is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 42.0% of the global market in 2025. The regional market is expanding given that the region has a strong base of biopharmaceutical companies, advanced biologics research centers, CDMOs, and analytical technology providers. As companies develop monoclonal antibodies, biosimilars, vaccines, and cell and gene therapies, they need better tools to control and confirm glycosylation patterns. The presence of large technology providers and high biologics R&D spending further supports the faster adoption of glycoengineering across discovery, process development, quality control, and commercial manufacturing.

• For instance, in June 2026, Thermo Fisher Scientific expanded its Orbitrap mass spectrometry platforms, AI-enabled software, and integrated workflows. These solutions support research, biopharma, and applied testing by helping scientists handle complex samples and generate confident results faster.

The European market is expected to grow at a significant CAGR during the forecast period. The region has a strong network of biologics manufacturers, academic research centers, and specialty technology providers. Since glycosylation directly affects biologic quality, activity, and consistency, European CDMOs are using integrated cell-line and process platforms to help biotechnology and pharmaceutical companies develop more scalable and controlled biologics. This is creating steady demand for glycoengineering technologies and prompting collaboration among key companies.

• For instance, in January 2026, ProBioGen partnered with Zag Bio to advance an Fc-fusion autoimmune therapy. Under the agreement, ProBioGen provided cell line development, process development, and GMP manufacturing using its CHO: riGHT expression platform, DirectedLuck transposase technology, and automated clone-screening approach.

Asia Pacific is expected to grow at a stable CAGR during the forecast period. The region is rapidly expanding its biologics, biosimilar, ADC, and advanced therapy development capabilities. As regional companies move from conventional biologics toward glycan-targeted antibodies, ADCs, and glycan-based platforms, the need for glycoengineering, glycan analysis, and glycan-conjugation technologies is increasing. This is making Asia Pacific an important growth region for both product development and technology collaboration.

• For instance, in February 2025, OBI Pharma showcased its proprietary site-specific glycan conjugation platform, GlycOBI, at the 2025 ADC Drug Development Conference in Suzhou, China. The platform gained strong industry interest due to its plug-and-play adaptability to any antibody and its development potential. Such development supports market growth.

Key Players Covered

The global glycoengineering market is moderately fragmented but increasingly consolidating.

The report includes the profiles of the following key players.

• Thermo Fisher Scientific Inc. (U.S.)
• Waters Corporation (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Shimadzu Corporation (Japan)
• Bruker Corporation (U.S.)
• Merck KGaA (Germany)
• New England Biolabs, Inc. (U.S.)
• Vector Laboratories, Inc. (U.S.)
• ProBioGen AG (Germany)
• FyoniBio GmbH (Germany)

Key Industry Developments

• June 2026: Combotope Therapeutics ApS collaborated with Boehringer Ingelheim. The partnership aimed to leverage Combotope's proprietary SMART-Phage platform to generate highly tumor-selective antibodies for next-generation cancer therapies. Combotope's approach is designed to identify antibodies that bind tumor-specific glycan structures together with their protein carriers.
• July 2025: Vector Laboratories, in collaboration with Navinci, launched the Glysite Explorer in situ PLA Glycan Detection Kit. The kit represented the first commercially available product to study protein glycosylation.